UC San Diego
Leads a $25.8M ARPA-H project to develop 3D bioprinted, patient-specific human livers using AI-driven design to overcome vascularization challenges, aiming to eliminate organ shortages and reduce donor waitlists.
- CEO / Founder
- Patty Maysent
- Team Size
- 10000+
- Stage
- Active
Technology & Products
Key Products
3D bioprinted patient-specific human livers; AI-driven design for vascularization; ARPA-H funded $25.8M research project to develop fully functional, transplantable human livers using stem cell technology and 3D bioprinting
Technological Advantage
Research-driven advantage in bioprinting complex tissues, supported by ARPA-H funding and academic expertise; defensible through intellectual property and collaborative partnerships.
Differentiation
Value Proposition
Enables on-demand production of functional, patient-specific livers, potentially reducing transplant wait times from years to weeks and improving patient outcomes by minimizing rejection risks.
How They Differentiate
Focuses on patient-specific liver bioprinting with AI integration for vascularization, unlike general bioprinting firms; backed by a major ARPA-H grant and academic research infrastructure.
Market & Competition
Target Customers
Healthcare providers, transplant centers, and patients in need of liver transplants.
Industry Verticals
Medical; Biotechnology
Competitors
Cell Applications, Inc.
Growth & Milestones
Growth Metrics
License revenue of $24 million and industry funding of $178.4 million, with 17 license startups, reflecting growth in commercialization and innovation.
Major Milestones
Received $25.8M ARPA-H award for 3D bioprinted liver project in 2026
Notable Customers
Allele Biotechnology (industry partner on ARPA-H liver bioprinting project); Collaborates with UC San Diego School of Medicine and Jacobs School of Engineering researchers